Statin intensity and postoperative mortality following open repair of intact abdominal aortic aneurysm.

Published online

Journal Article

Background: There is a lack of evidence for the association between intensive statin therapy and outcomes following vascular surgery. The aim of this study was to evaluate the association between perioperative statin intensity and in-hospital mortality following open abdominal aortic aneurysm (AAA) repair. Methods: Patients undergoing open AAA repair between 2009 and 2015 were identified from the Premier Healthcare Database. Statin use was classified into low, moderate and high intensity, based on American College of Cardiology/American Heart Association guidelines. Supratherapeutic intensity was defined as doses higher than the recommended guidelines. Multivariable logistic regression analyses were undertaken to assess the association between statin intensity and postoperative major adverse events and in-hospital mortality. Results: Of 6497 patients undergoing open AAA repair, 3217 (49·5 per cent) received perioperative statin. Statin users were more likely to present with three or more co-morbidities than non-users (26·5 versus 21·8 per cent; P < 0·001). Unadjusted postoperative mortality was significantly lower in statin users (2·6 versus 6·3 per cent; P < 0·001); however, there was no difference in the risk of developing major adverse events. Multivariable analysis showed that statin use was associated with lower odds of death (odds ratio 0·41, 95 per cent c.i. 0·31 to 0·54). Moderate, high and supratherapeutic statin intensities were not associated with lower odds of death or major adverse events compared with low-intensity statin therapy. Conclusion: Statin use is associated with lower odds of death in hospital following open AAA repair. High-intensity statins were not associated with lower morbidity or mortality.

Full Text

Duke Authors

Cited Authors

  • Alshaikh, HN; Bohsali, F; Gani, F; Nejim, B; Malas, M

Published Date

  • December 2018

Published In

Volume / Issue

  • 2 / 6

Start / End Page

  • 411 - 418

PubMed ID

  • 30511041

Pubmed Central ID

  • 30511041

Electronic International Standard Serial Number (EISSN)

  • 2474-9842

Digital Object Identifier (DOI)

  • 10.1002/bjs5.94


  • eng

Conference Location

  • England